Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 881, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2020.173208
Keywords
Glaucoma; Neuroprotection; Genetics; Nanoplatforms
Categories
Funding
- Department of Science and Technology (DST), Government of India, New Delhi
- Manipal Academy of Higher Education, Manipal
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal
Ask authors/readers for more resources
In most retinal diseases, neuronal loss is the main cause of vision loss. Neuroprotection is the alteration of neurons and/or their environment to encourage the survival and function of the neurons, especially in environments that are deleterious to the neuronal health. The area of neuroprotection progresses with a therapeutically-based hope of improving vision and clinical outcomes for patients through the developments in neurotrophic therapy, antioxidative therapy, anti-excitotoxic, anti-ischemic, anti-inflammatory, and anti-apoptotic care. In this review, we summarize the various neuroprotection strategies for the treatment of glaucoma, genetics of glaucoma and the role of various nanoplatforms in the treatment of glaucoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available